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Letter
CD40-activated B cells (CD40-B cells) have been demonstrated to
expand memory and prime naı¨ve CD8 T cells in healthy individuals
and cancer patients (1–6). These findings are of particular interest to
the cancer vaccine field because CD40-B cells are reliably expandable
from small amounts of peripheral blood without the technical limita-
tions encountered using dendritic cells, especially in pediatric pa-
tients. A growing number of investigators have started to use CD40-B
cells instead of, or in combination with, dendritic cells, and first
clinical trials are under way (2, 3, 7–10). Nevertheless, it remains
unclear whether B cells used as antigen-presenting cells might have
significant biological limitations when used as cellular adjuvant. B
cells take up and present antigen primarily and most efficiently via
highly epitope-specific B-cell receptors (11, 12). Moreover, naı¨ve B
cells have been shown to induce CD4 T-cell tolerance (13). It,
therefore, remained unclear whether ex vivo-generated polyclonal
CD40-B cells, especially under long-term culture conditions, have the
capacity to take up, process, and present a broad range of antigens to
CD4 T-cells. This is of particular importance because CD4 T-cell
responses are crucial for successful tumor rejection (14–16).
Lapointe et al. (17) addressed this important question in this journal
and demonstrated that CD40-B cells generate tumor antigen-specific
CD4 T cells in cancer patients when the B cells are pulsed with lysate
from tumor cells (17). The authors conclude that these findings empha-
size the role of CD40-B cells as antigen-presenting cells for immuno-
therapy. Melanoma antigen-specific T cells were generated from the
peripheral blood mononuclear cells of two melanoma patients. Because it
is most likely that these melanoma antigen-specific T cells derived from
melanoma patients were expanded from a preexisting population of
memory T cells, it remains to be shown whether CD40-B cells also prime
naı¨ve CD4 T cells against neoantigens as demonstrated for CD8
T-cells (2). This would also extend their potential use to neoantigens such
as viral antigens or previously ignored potential tumor antigens. Most
likely because of low antigen concentration in tumor lysates, Lapointe et
al. reported a rather low efficacy of expansion of CD4 T cells after
stimulation with CD40-B cells, (17), whereas antigen-specific CD8 T
cell expansion was successful in more than 80% of individuals tested (2,
6). Here, we have addressed the induction of naı¨ve CD4 T-cell re-
sponses and the efficacy of ex vivo CD4 T-cell expansion by stimulation
with CD40-B cells.
The system used for CD8 T cells (1, 2) was modified to allow
for optimal induction of antigen-specific CD4 T-cell responses to
whole proteins (tetanus toxoid and keyhole limpet hemocyanin),
and to the artificial promiscuous MHC class II binding peptides
PADRE-AKF and PADRE-AKX, serving as peptide-neoantigens
(18). T-cell expansion and cytokine production were assessed after
2–5 stimulations in vitro with protein- or peptide-loaded CD40-B
cells in at least four T-cell lines against each of the antigens. T-cell
responses against tetanus toxoid were induced in four of four
T-cell lines. Similarly, two of four and three of four T-cell lines
were antigen-specific to PADRE AKX and PADRE-AKF (Fig. 1,
A and B). Analysis for IFN- or interleukin-4 production did not
reveal any skewing toward a TH1 or TH2 profile. Successful
generation of antigen-specific CD4 T cells in this optimized
system was possible in 9 (75%) of 12 of T cell lines.
Antigen uptake by CD40-B cells was mainly due to fluid-phase
uptake as demonstrated by Lucifer yellow incorporation and compa-
rable with immature dendritic cells. As expected, mannose receptor-
mediated antigen uptake (Dextran-FITC loading) was low compared
with immature dendritic cells. (Fig. 1C). Even for molecules larger
than Lucifer yellow, the MHC class II pathway of antigen uptake,
processing and presentation is fully functional in CD40-B cells, as
demonstrated by reduced T-cell activation by keyhole limpet hemo-
cyanin and tetanus toxoid when using agents interfering with endo-
cytosis (2-deoxyglucose, NaN3), early and late lyso-/endosomal trans-
port (chloroquine; bafilomycin A, data not shown), recycling
(primaquine), trafficking of newly synthesized molecules (brefeldin
A), loading (cathepsin inhibitor), and presentation by MHC class II
molecules (MHC class II monoclonal antibody; Ref. 19; (Fig. 1D).
With this in mind, we extended the initial findings by Lapointe et
al. (17) and clearly demonstrated that CD40-B cells efficiently proc-
ess and present antigen not only to memory but also to naı¨ve CD4
T cells and that it is possible to reliably expand antigen-specific T
cells with CD40-B cells as antigen-presenting cells. These findings
significantly widen the potential of CD40-B cells for immunotherapy.
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Reply
Antigen-specific B lymphocytes have the capacity to uptake
antigens with surface antibody and present epitopes to specific
CD4 T cells. The process involves cross-communication between
B and T lymphocytes involving CD40L expression and cytokine
secretion from T lymphocytes, which will then modify B-cell
biology (1). This is central and critical in the development of
humoral responses. Recently, CD40-activated B cells were ex-
ploited as a source of antigen-presenting cells in the in vitro
generation of CD8 T lymphocytes specific to viral (2) and tumor
antigens (3–5). Several strategies were exploited to load antigens
in CD40-activated B cells, including peptide pulsing (3), RNA
transfection (6), and retroviral transduction (2). Interestingly,
CD40-activated B cells were found to be comparable with den-
dritic cells in their capacity to raise antigen-specific CD8 T cells
(3, 6). In addition, it has been demonstrated that the culture of
CD40-activated B cells is technically easier compared with that of
dendritic cells, and requires only small numbers of peripheral
blood mononuclear cells (3).
We have reported recently in this journal that CD40-activated B
cells also have the capacity to present exogenous tumor antigens to
CD4 T cells in an immunostimulatory fashion (7). We appreciate
the positive comments and additional data provided by von Berg-
welt-Baildon et al. (8) supporting our claims. Indeed, they previ-
ously succeeded in generating antigen-specific naı¨ve and memory
CD8 T cells against different antigens (5, 8). On several occa-
sions, von Bergwelt-Baildon and collaborators generated specific
T cells in a high proportion of individuals, using purified peptides
or proteins as a source of antigen. This contrasts with our strategy
of preparing a crude lysate from tumor cells. Although the use of
lysates is advantageous in that multiple antigens, including unde-
scribed antigens, may be represented, the concentration of any
Fig. 1. Antigen processing and generation of antigen-specific
CD4 T cells. A, priming of naive CD4 T cells. Secretion of
IFN- (IFN-)and interleukin 4 (IL-4) by antigen-specific CD4 T
cells on recognition of the peptides PADRE AKX or PADRE
AKF). CD40-activated B cells (CD40-B cells) were pulsed over-
night with irrelevant control (C) antigen or relevant antigen (E,
experiment). Secretion of cytokines was measured by enzyme-
linked immunospot assay (ELISPOT). The spot-forming units in-
dicate the number of cytokine secreting CD4 T-cells out of 105
cells. B, expansion of antigen-specific CD4 T cells. The table
shows the number of antigen-specific T cell lines out of total
number of primary T cell lines stimulated with loaded-pulsed
CD40-B cells; TT, tetanus toxoid. Antigen specificity was assessed
after 2–5 restimulations. Antigen- reactivity was assessed by either
antigen-specific proliferation or cytokine production (by ELISPOT
analysis). If no antigen-specific proliferation or cytokine produc-
tion (three SD over background) was detectable, T-cell lines were
judged as nonspecific. C, antigen uptake. CD40-B cells (F) and
monocyte-derived immature dendritic cells (E) were loaded with
Lucifer yellow (left panel) or with Dextran-FITC (right panel) at
37°C, to exclude unspecific binding at 4°C (data not shown).
Antigen uptake was quantified at various time points using flow
cytometry; MFI, mean fluorescent intensity. (One representative
experiment out of three.) D, antigen processing. CD40-B cells
were loaded with keyhole limpet hemocyanin (KLH, left panel) or
TT (right panel) for 18 h and cells were incubated with a KLH- or
a TT-specific autologous T-cell line generated by weekly stimu-
lations of purified CD4 T cells with antigen-pulsed CD40-B
cells. Chemical compounds and antibodies were used to inhibit
antigen processing at pivotal steps; 2-deoxyglu., deoxyglucose;
Brefeld. A, brefeldin A; Primaq., primaquine; Chloroq., chloro-
quine; Cath. Inhib., cathepsin inhibitor; ab, antibody. Proliferation
(measured by thymidine incorporation; proliferation with TT or
KLH alone set to 100%) above background (no antigen) is shown.
(Two representative experiments out of five.)
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particular antigen is likely to be low, perhaps limiting the effi-
ciency of T cell generation against a specific antigen compared
with the use of purified proteins or peptides. In their Letter to the
Editor, von Bergwelt-Baildon et al. (8) convincingly present data
demonstrating the efficiency of CD40-activated B cells in the
generation of naı¨ve, specific CD4 T cells against several foreign
antigens with purified proteins.
Many tumor antigens that have been described are “self” anti-
gens and may be more challenging to use, compared with foreign
antigens, to generate specific immune responses because of toler-
ance mechanisms. To explore the ability of CD40-activated B cells
pulsed with purified proteins to generate immune responses to self
antigens, we performed studies with recombinant gp100 protein, an
antigen expressed on melanoma cells as well as normal melano-
cytes. With peripheral blood mononuclear cells and CD40-acti-
vated B cells prepared from five different HLA-DR1*0701
melanoma patients, several gp100-reactive T-cell lines were suc-
cessfully generated from three patients (Table 1). Interestingly,
T-cell lines generated from two of the patients were specific to
an HLA-DR1*0701 epitope (gp100170 –190) that we had identi-
fied previously (9). Also, T-cell lines potentially specific to new
gp100 epitopes were raised (Table 1; patient 1 T-cell line B, and
patient 2).
Interestingly, von Bergwelt-Baildon et al. demonstrated the abil-
ity of these activated B cells to take-up and process exogenous
antigens. We suggested that the observed down-regulation of
HLA-DO is involved in the efficient antigen presentation by acti-
vated B cells (7). This is in line with recent studies by different
groups elegantly showing that germinal center B lymphocytes express
very little HLA-DO as compared with naı¨ve or memory populations
(10–12). The assumption that DO down-regulation plays a role in our in
vitro systems will need to be addressed directly and for each model
antigen (13).
Considering all of the data we obtained thus far, and the additional
evidence presented in the Letter to the Editor from von Bergwelt-
Baildon et al. (8), we believe CD40-activated B cells have significant
potential as a source of antigen-presenting cells for the generation of
CD4 T cells specific to foreign or tumor antigens.
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Table 1 Generation of gp100-specific T cells from melanoma patients
Peripheral blood mononuclear cells from HLA-DR1*0701 melanoma patients were
incubated with recombinant gp100 (rgp100) for 7 days, and CD40-activated B cells were
prepared concomitantly. Cultured T cells were restimulated with rgp100-pulsed CD40-
activated B cells, and 60 IU/ml of interleukin-2 (IL-2) were added every 3 days. T-cell
specificity was evaluated using autologous CD40-activated B cells pulsed with different
concentrations of a DR1*0701 epitope from gp100 (gp100170–190) or a control peptide
(Igk188–201), or with rgp100 or recombinant NY-ESO-1 (rNY-ESO-1). Alternatively, T
cells were cocultured with melanoma cell lines engineered to express MHC class II after
CIITA expression or treatment with IFN- (except for 836mel). T-cell reactivity was
assessed by IFN- secretion ELISA (pg/ml). Patient 2 and 888mel share HLA-DQ1*06.
Bold and underline values are twice the background and higher than 100 pg/ml.
DR1*
0701
Class
II
Patient 1
Patient
2
Patient
3
T-cell
line A
T-cell
line B
Pulsed B cells
Medium   210 576 213 24
gp100170–190 50 M   3,368 781 179 1,991
gp100170–190 10 M   1,925 581 174 879
gp100170–190 1 M   1,990 526 289 215
Igk188–201   207 364 144 19
rgp100   7,425 2,530 2,115 >5,000
rNY-ESO-1   182 388 27 55
Tumors
1087mel   172 453 17 39
624.38mel   1,329 6,275 135 >5,000
pt1mel/gp100   24,500 48,250 24 >5,000
pt1mel/GFP   122 64 14 8
836mel   173 99 NAa NA
888mel   155 17 1,328 NA
1102mel   NA NA 45 228
1088mel   NA NA 97 8
a NA, not available.
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